Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gossamer Bio
Biotech
Gossamer Bio fails phase 3 pulmonary arterial hypertension trial
An executive said the outcome is less about a lack of drug activity and more about placebo, particularly in a heavily treated lower risk population.
Nick Paul Taylor
Feb 23, 2026 9:50am
Chiesi buys into Gossamer's Winrevair rival
May 6, 2024 10:28am
Former FDA leader Woodcock inspires Biotech Sisterhood summit
Apr 24, 2024 9:23am
BIO announces new CEO—Chutes & Ladders
Dec 8, 2023 9:30am
Gossamer cuts loose staff, ties future to tarnished Merck rival
May 10, 2023 6:30am
Gossamer halts work on BTK inhibitor after 2 patient deaths
Apr 4, 2023 4:30am
